Trials / Completed
CompletedNCT02387853
Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis
Safety and Effect of LEO 90100 Aerosol Foam on the HPA Axis and Calcium Metabolism in Adolescent Subjects (Aged 12 to < 17 Years) With Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- LEO Pharma · Industry
- Sex
- All
- Age
- 12 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
An international, multi-centre, prospective, open-label, non-controlled, single-group, 4-week trial in adolescent subjects with plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LEO 90100 |
Timeline
- Start date
- 2016-03-01
- Primary completion
- 2018-03-28
- Completion
- 2018-03-28
- First posted
- 2015-03-13
- Last updated
- 2025-03-10
- Results posted
- 2019-01-15
Locations
9 sites across 4 countries: United States, Netherlands, Poland, Romania
Source: ClinicalTrials.gov record NCT02387853. Inclusion in this directory is not an endorsement.